Phase II study of rucaparib and nivolumab in patients with leiomyosarcoma
Background Objective responses to immune checkpoint inhibitors (ICI) in leiomyosarcoma (LMS) are rare. Response rates may be increased by combination with other drugs known to promote immune infiltration, such as poly(ADP-ribose) polymerase (PARP) inhibitors, which have led to benefit in BRCA-altere...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
BMJ Publishing Group
2025-06-01
|
| Seri Bilgileri: | Journal for ImmunoTherapy of Cancer |
| Online Erişim: | https://jitc.bmj.com/content/13/6/e012020.full |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|
